Patrick Mehlen is director of the Translational Research and Innovation at the Léon Bérard Comprehensive Cancer Center in Lyon, France, director of the “Laboratoire d’Excellence” DEVweCAN, deputy-director of the Research Cancer Center. He is adjunct professor at the Buck Institute for Age Research, California. He has published over 150 peer-reviewed scientific publications and has received several awards including the silver medal from CNRS or the Pius XI Gold Medal from Pontificia Academia Scientiarum. Dr. Mehlen has been elected EMBO member in 2006 and member of the French Academy of Sciences in 2013. Dr. Mehlen is co-founder and CEO of Netris Pharma, a SME developing cancer therapies based on the dependence receptor concept.